NEWS

Position:

Corporate News

Media coverage

Corporate Announcement

Shi Si Yao Group Guangxiang Pharmaceutical has been approved to establish a postdoctoral research workstation.

Category:

Corporate Announcement

Time:2020-11-21

【概要描述】 Recently, the Ministry of Human Resources and Social Security of China and the National Postdoctoral Administration Committee approved Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shisi Pharmaceutical Group, to establish a postdoctoral research workstation and launch postdoctoral programs. This marks another significant step taken by Shisi Pharmaceutical Group to attract and cultivate high-level talents, strengthen collaboration among industry, academia, research, and application, and continuously enhance its independent innovation capabilities.

Recently, the Ministry of Human Resources and Social Security of China and the National Postdoctoral Administration Committee approved Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shisi Pharmaceutical Group, to establish a postdoctoral research workstation and launch postdoctoral programs. This marks another significant step taken by Shisi Pharmaceutical Group to attract and cultivate high-level talent, strengthen collaboration among industry, academia, research, and application, and continuously enhance its independent innovation capabilities.

It is understood that a postdoctoral research workstation refers to an organization—approved to recruit and train postdoctoral researchers—that is established within enterprises, research-and-production-oriented institutions, and specialized regional agencies. Such workstations serve as an effective platform for integrating industry, academia, and research, thereby enhancing enterprises’ independent innovation capabilities. They play a crucial role in attracting and gathering postdoctoral talent, boosting enterprises’ technological innovation, and promoting the commercialization of scientific and technological achievements.
A relevant official from Shiyao Group stated that the group’s Guangxiang Pharmaceutical has been approved to establish a postdoctoral research workstation, which will facilitate the cultivation of high-end talent and the research and implementation of innovative projects. This initiative will promote pragmatic cooperation between enterprises and universities and research institutions, strengthen and expand the team of scientific researchers and innovators, continuously enhance independent R&D and innovation capabilities, bolster the company’s core competitiveness, and play a positive role in driving the company’s healthy, sustainable, and rapid development.
“Build a thriving banyan tree, and the phoenix will naturally come.” Since its completion and commissioning, Shisi Pharmaceutical Group Guangxiang Pharmaceutical has steadily improved its production scale and research & development capabilities, and its innovation capacity-building has entered a fast track. Han Shuqin, Chairperson of Shisi Pharmaceutical Group Guangxiang Pharmaceutical, stated that in the future, the company will leverage the group’s advantage in attracting talent, increase investment in scientific research, and firmly advance and implement cooperative mechanisms for jointly training postdoctoral fellows with universities and research institutes both at home and abroad. By fully harnessing the complementary strengths of enterprises—particularly in technology and practical application—and universities and research institutes—in terms of faculty and basic research—the company will accelerate research projects at its postdoctoral workstations, solidify the foundation for cultivating high-level, versatile talents, and truly enable the postdoctoral workstations to play their role in driving scientific and technological progress, thereby supporting the high-quality development of Shisi Pharmaceutical Group Guangxiang Pharmaceutical.